Serán CEO Dan Smithey on the Future of Oral GLP-1 Therapies: “A Rare Opportunity for CDMOs”
Home
News & Events
Serán CEO Dan Smithey on the Future of Oral GLP-1 Therapies: “A Rare Opportunity for CDMOs”

Serán CEO Dan Smithey on the Future of Oral GLP-1 Therapies: “A Rare Opportunity for CDMOs”

May 6
-

In The Pharma Navigator’s recent feature “Riding the Oral GLP-1 Wave”, Serán CEO and Co-founder Dr. Dan Smithey discusses the critical role Contract Development and Manufacturing Organizations (CDMOs) will play in the future of GLP-1 drug development—particularly as the market pivots toward oral delivery.

Dr. Smithey emphasizes the challenges of developing orally bioavailable molecules, noting that many pharmaceutical companies lack the specialized manufacturing techniques required for early-stage development. “Molecules that are orally bioavailable are difficult to develop and will likely require manufacturing techniques that are not widely available internally in many pharmaceutical companies, thus requiring outsourcing to CDMOs who have this technology,” he explains.

Serán is positioned at the forefront of this transformation, offering deep expertise in advanced formulation development, solid-dose manufacturing, and scalable production. Dr. Smithey highlights the necessity of CDMOs to invest in GMP-compliant equipment, resilient supply chains, and regulatory strength to serve the emerging markets for GLP-1s.

He concludes with a call to action: “The scale of manufacturing that will be required [for success in the GLP-1 arena] is massive, and will require investment from CDMOs, pharma, and likely government.”

As the industry prepares for a paradigm shift in how GLP-1 therapies are developed and delivered, Serán stands ready to support partners with the technologies, capabilities, and scale necessary to lead in this rapidly evolving field.

Read more about Serán’s capabilities in oral solid dosage formulation at www.seranbio.com.

Download article

About Serán

Serán BioScience, LLC, is a science-driven drug development partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.

For more information, email us at hello@seranbio.com.

Contact

Brinette Holdren
Director of Marketing

Serán BioScience, LLC
63047 Layton Ave,
Bend, OR 97701 USA

Phone: (541)-237-8501
www.seranbio.com

Ready to get started?

Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product.